Last update: Oct. 20, 2016
Minimal risk for breastfeeding and infant.
It is excreted into breast milk in clinically non-significant amount, in any case, much lower than the doses commonly used in newborns and infants (Snider 1984, Singh 2008).
No significant problems have been observed in infants whose mothers were treated. (Drobac 2005). An infant whose mother was treated with anti-TBC drugs during pregnancy and lactation for 7 months, presented moderately high levels of liver transaminases along with a normal clinical and developmental course (Peters 2008).
The plasma levels measured in any of those infants were undetectable or very low.
Several medical societies and consensus of expert panels consider safe the use of this medication while breastfeeding (Dautzenberg 1988, Tran 1998, Blumberg 2003, Schram 2005, WHO 2007, Singh 2008, Baquero-Artigao 2015, Malhamé 2016).
American Academy of Pediatrics: medication usually compatible with breastfeeding.
WHO List of Essential Medicines 2002: compatible with breastfeeding.
The addition of Vitamin B6 (Pyridoxine) to treatment of mother-infant dyad should be evaluated, especially in cases of malnutrition, diabetes, other diseases or a new pregnancy (Blumberg 2003, Steichen 2006, Baquero-Artigao 2015, 2016 Principi Di 2016).
We do not have alternatives for Isonicotinic Acid Hydrazide since it is relatively safe.
Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine from United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM